GlassScriptPhysician profile
Renato Augusto Berger
NPI 1811994528
$2,827.51
in general payments reported to CMS, 2019-2025
23 companies · $472 in 2025
The $472 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $365 · 2021: $402 · 2022: $399 · 2023: $306 · 2024: $463 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $578.40 | 2021-2025 | Azstarys |
| Tris Pharma INC | $419.21 | 2019-2022 | |
| Glaxosmithkline, LLC. | $273.12 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Cranial Technologies, INC | $209.64 | 2019-2025 | Doc Band |
| Pfizer INC. | $168.11 | 2019-2024 | |
| Adlon Therapeutics L.P. | $143.79 | 2019-2021 | |
| Seqirus USA INC | $111.86 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $105.90 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $100.58 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $96.98 | 2019-2025 | |
| Alk-Abello, INC | $83.95 | 2023-2025 | Grastek, Odactra, Neffy |
| Sanofi-Aventis U.S. LLC | $82.43 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $79.65 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $73.01 | 2019-2024 | |
| Phadia US INC. | $65.01 | 2019-2024 | Immunocap |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $48.89 | 2024-2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $46.33 | 2024 | Flumist Quadrivalent |
| Abbvie INC. | $32.55 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $25.54 | 2025 | Daybue |
| Springworks Therapeutics, INC. | $25.21 | 2025 | Gomekli |
| Biomarin Pharmaceutical INC. | $24.41 | 2022 | |
| Shire North American Group INC | $17.67 | 2019 | |
| Mission Pharmacal Company | $15.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renato Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.